A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2001
11/08/2001	WO2001083454A1 Benzosuberonylpiperidine compounds as analgesics
11/08/2001	WO2001083434A2 P-(sulfonyl)-aryl and heteroaryls amines
11/08/2001	WO2001083427A1 PPARη MODULATORS
11/08/2001	WO2001083425A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	WO2001082975A2 Membrane-permeant peptide complexes for medical imaging
11/08/2001	WO2001082968A1 Cell proliferation inhibitors
11/08/2001	WO2001082967A1 MEDICINAL COMPOSITIONS FOR SUPPRESSING β-AMYLOID PRODUCTION
11/08/2001	WO2001082954A2 Ceruloplasmin and uses thereof in neurodegenerative related conditions
11/08/2001	WO2001082949A2 Method of reducing side effects of chemotherapy in cancer patients
11/08/2001	WO2001082946A2 Neuroprotective compositions
11/08/2001	WO2001082940A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001	WO2001082939A1 Treatment of conditions of the central nervous system using mycobacteria
11/08/2001	WO2001082928A1 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
11/08/2001	WO2001082923A1 Estrogen receptor modulators
11/08/2001	WO2001082919A2 Methods of and compounds for inhibiting calpains
11/08/2001	WO2001082914A2 Topical anesthetic/opioid formulations and uses thereof
11/08/2001	WO2001082900A1 Non-invasive gene targeting to the brain
11/08/2001	WO2001082888A1 Lipochroman-6 as no-synthase inhibitor and uses
11/08/2001	WO2001060349A3 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.
11/08/2001	WO2001056567A8 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001	WO2001038564A3 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
11/08/2001	WO2001038331A3 Pyrazolo[1,5-d][1,2,4]triazines for enhancing cognition
11/08/2001	WO2001037780A8 Urotensin-ii analogs
11/08/2001	WO2001034183A3 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
11/08/2001	WO2001032614A3 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
11/08/2001	WO2001030383A3 Medicament in order to induce tolerance
11/08/2001	WO2001029012A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	WO2001029011A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	WO2001028574A3 Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain
11/08/2001	WO2001010846A3 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
11/08/2001	WO2000074666A3 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
11/08/2001	WO2000041683A3 Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids
11/08/2001	US20010039343 Pesticides, fungicides, herbicides, insecticides, microbiocdes, drugs
11/08/2001	US20010039294 11-beta-reductase inhibitor such as carbenoxolone to control 11-keto steroid conversion to 11-beta-hydroxysteroid; antidiabetic agents
11/08/2001	US20010039284 Acetylcholine enhancers
11/08/2001	US20010039280 Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists
11/08/2001	US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001	US20010039273 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
11/08/2001	US20010039271 For treatment of male erectile dysfunction, female sexual dysfunction
11/08/2001	US20010039261 Administration of polypeptide growth factors following central nervous system ischemia or trauma
11/08/2001	US20010039038 Novel glucosaminidase
11/08/2001	EP1143938A3 Phinan
11/08/2001	DE10019755A1 New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes
11/08/2001	CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2408105A1 Novel proteases
11/08/2001	CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	CA2407959A1 Human wingless-like gene
11/08/2001	CA2407781A1 Ceruloplasmin and uses thereof in neurodegenerative related conditions
11/08/2001	CA2407746A1 Proteases
11/08/2001	CA2407597A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001	CA2407594A1 Muscarinic agonists
11/08/2001	CA2407587A1 Ppar.gamma. modulators
11/08/2001	CA2407435A1 Rna metabolism proteins
11/08/2001	CA2407418A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001	CA2407399A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/08/2001	CA2407334A1 Lipochroman-6 as no-synthase inhibitor and uses
11/08/2001	CA2407294A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001	CA2407219A1 Pain signaling molecules
11/08/2001	CA2407136A1 Treatment of conditions of the central nervous system using mycobacteria
11/08/2001	CA2406999A1 Gene and sequence variation associated with sensing carbohydrate compounds and other sweeteners
11/08/2001	CA2405832A1 P-(sulfonyl)aryl and heteroaryls
11/08/2001	CA2405745A1 New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments
11/08/2001	CA2405611A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	CA2404936A1 (5r)-(methylamino)-5,6-dihydro-4h-imidazo¬4,5,1-ij\|quinoline-2(1h)-thione
11/07/2001	EP1152055A1 ADAMTS polypeptides, nucleic acids encoding them, and uses therof
11/07/2001	EP1152002A1 Pyrrole derivatives and cell death inhibitors
11/07/2001	EP1151995A1 Process for the preparation of the mesylate salt trihydrate of 1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-Phenylpiperidin-1-YL)-1-Propanol
11/07/2001	EP1151100A1 Tau-conotoxin peptides
11/07/2001	EP1151067A1 Process of converting rendered triglyceride oil from marine sources into bland, stable oil
11/07/2001	EP1150997A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
11/07/2001	EP1150991A2 Compositions for treating inflammatory response
11/07/2001	EP1150983A1 Triazolo-pyridazine derivatives as ligands for gaba receptors
11/07/2001	EP1150982A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I$g(k)-A$g(a)
11/07/2001	EP1150979A1 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
11/07/2001	EP1150978A1 Carbamate derivatives of diaryl 1,3,4-oxadiazolone
11/07/2001	EP1150977A1 Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
11/07/2001	EP1150976A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
11/07/2001	EP1150974A1 Heterocyclic derivatives as inhibitors of factor xa
11/07/2001	EP1150972A1 Triazole and tetrazole derivatives, and their therapeutic use
11/07/2001	EP1150971A1 Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation
11/07/2001	EP1150970A1 (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
11/07/2001	EP1150963A1 Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them
11/07/2001	EP1150961A1 Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them
11/07/2001	EP1150960A1 Polymorphic crystalline forms of celecoxib
11/07/2001	EP1150959A1 Solid-state form of celecoxib having enhanced bioavailability
11/07/2001	EP1150955A2 G-protein coupled heptahelical receptor binding compounds and methods of use thereof
11/07/2001	EP1150954A1 Anti-imflammatory indole derivatives
11/07/2001	EP1150953A1 Indole derivatives and their use as mcp-1 receptor antagonists
11/07/2001	EP1150950A2 Anthranilic acid derivatives
11/07/2001	EP1150715A1 Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms
11/07/2001	EP1150703A1 Chaperonin 10 and beta-interferon therapy of multiple sclerosis
11/07/2001	EP1150681A2 Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
11/07/2001	EP1150678A1 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
11/07/2001	EP1150676A1 Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
11/07/2001	EP1150672A1 Method to aid smoking cessation
11/07/2001	EP1150667A1 Use of a cyclohexenone long-chain alcohol for treating neurodegenerative diseases
11/07/2001	EP1150664A2 Novel use of orexin receptor antagonists

1 ... 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 ... 1833